SCHEMBL1586715

SCHEMBL1586715

NCC1(NCc2ccccc2)CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HIF1A Q16665 1/20 0.41
OPRM1 P35372 1/20 0.39
IDO1 P14902 2/20 0.38
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CYP2D6 P10635 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
GBA1 P04062 1/20 0.36
NPFFR1 Q9GZQ6 1/20 0.36
NPFFR2 Q9Y5X5 1/20 0.36
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
TAAR1 Q96RJ0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9954933 0.84 DPP4 (0.44) MEN1TSHRKMT2AIDO1CYP3A4
SCHEMBL1586598 0.84 ALDH1A1 (0.42) TACR1MEN1ALDH1A1CYP2C9TSHR
SCHEMBL1586350 0.84 CYP2D6 (0.44) MEN1ALDH1A1CYP2C9TSHRCYP2C19
SCHEMBL15824244 0.83 DPP4 (0.43) ALDH1A1TSHRKMT2AIDO1CYP3A4
SCHEMBL1587373 0.81 SIGMAR1 (0.43) TACR1MEN1ALDH1A1CYP2C9TSHR
SCHEMBL4082174 0.81 CYP3A4 (0.41) TACR1ALDH1A1CYP2C9TSHRIDO1
SCHEMBL20787990 0.81 TACR1 (0.45) TACR1MEN1ALDH1A1CYP2C9TSHR
SCHEMBL1587054 0.80 ALDH1A1 (0.45) TACR1MEN1ALDH1A1KMT2AIDO1
SCHEMBL14999534 0.80 IDO1 (0.38) MEN1ALDH1A1CYP2C9TSHRCYP2C19
SCHEMBL21561469 0.80 TACR1 (0.46) TACR1MEN1ALDH1A1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444120-B1 Spirocyclic amiloride analogues as ENac blockers NOVARTIS AG (CH) 2017-09-27 EP disclosed
EP-2490687-A1 COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES Vertex Pharmaceuticals Incorporated (US) 2012-08-29 EP disclosed
WO-2011050325-A1 COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-28 WO disclosed
EP-2231280-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-09-29 EP disclosed
WO-2009074575-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-06-18 WO disclosed